Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Financing Activities (2016 - 2026)

Intellia Therapeutics has reported Cash from Financing Activities over the past 12 years, most recently at $33.6 million for Q1 2026.

  • Quarterly Cash from Financing Activities changed N/A to $33.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $165.1 million through Mar 2026, up 31.25% year-over-year, with the annual reading at $131.5 million for FY2025, 29.21% down from the prior year.
  • Cash from Financing Activities was $33.6 million for Q1 2026 at Intellia Therapeutics, up from $2.0 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $505.8 million in Q4 2022 and troughed at $2.0 million in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $28.8 million (2022), against an average of $66.5 million.
  • Year-over-year, Cash from Financing Activities surged 22082.59% in 2022 and then crashed 97.82% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $505.8 million in 2022, then crashed by 78.95% to $106.5 million in 2023, then crashed by 97.82% to $2.3 million in 2024, then decreased by 14.67% to $2.0 million in 2025, then soared by 1597.98% to $33.6 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Cash from Financing Activities are $33.6 million (Q1 2026), $2.0 million (Q4 2025), and $114.9 million (Q3 2025).